Alembic Pharma receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Mumbai, November 06th 2026: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pataday Once Daily Relief,…
